NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

心脏衰竭 (HF):全球治疗药市场预测与分析 (到2028年)

Heart Failure: Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品编码 296455
出版日期 内容资讯 英文 190 Pages
订单完成后即时交付
价格
心脏衰竭 (HF):全球治疗药市场预测与分析 (到2028年) Heart Failure: Global Drug Forecast and Market Analysis to 2028
出版日期: 2019年12月31日内容资讯: 英文 190 Pages
简介

本报告提供全球心脏衰竭 (HF) 治疗药的市场相关分析,疾病概要和流行病学的背景,患病人数趋势预测,临床实验的进展,已上市/临床实验中主要的调查治疗药,目前市场未满足需求,主要企业的简介,全球/主要国家的市场趋势预测等。

第1章 目录

第2章 心脏衰竭:摘要整理

第3章 简介

第4章 疾病概要

  • 病因、病理生理学
  • 分类、病期分类系统
  • 症状
  • 预后

第5章 流行病学

  • 疾病的背景情况
  • 风险要素与并存症
  • 世界各国的变化
  • 预测手法
    • 资讯来源
    • 预测的前提条件与手法
  • 心脏衰竭 (HF)的流行病学的预测 (2018~2028年)
    • 心脏衰竭的已受诊患病人数
    • 心脏衰竭的已受诊患病人数:各年龄
    • 心脏衰竭的已受诊患病人数:男女
    • 心脏衰竭的已受诊患病人数:各射血分数 (EF)
    • 急性心脏衰竭 (AHF)的住院患者数
    • 急性心脏衰竭 (AHF) 患者的住院期间
    • 急性心脏衰竭 (AHF) 患者的再住院率 (30日以内)
    • 慢性心脏衰竭 (CHF)的已受诊患病人数
    • 慢性心脏衰竭 (CHF)的已受诊患病人数:各射血分数 (EF)
    • 慢性心脏衰竭 (CHF)的已受诊患病人数:各年龄
    • 慢性心脏衰竭 (CHF)的已受诊患病人数:男女
    • 慢性心脏衰竭 (CHF)的已受诊患病人数:NYHA各分类
    • 扩充性 (PEF)、慢性心脏衰竭 (CHF)的已受诊患病人数:各NYHA分类
    • 收缩性 (REF)、慢性心脏衰竭 (CHF)的已受诊患病人数:各NYHA分类
    • 慢性心脏衰竭 (CHF)的已受诊患病人数:ACCF/AHA分类
  • 讨论
    • 流行病学预测相关考察
    • 分析的限制
    • 分析的优势

第6章 疾病管理

  • 诊断概要
  • 治疗方法概要
    • 治疗的指南代表性处方药
    • 临床诊疗
  • 美国
  • (5EU)欧洲主要5个国家
  • 日本
  • 中国

第7章 竞争评估

  • 概要

第8章 未满足需求及市场机会分析

  • 概要
  • 扩张性心脏衰竭 (HF-PEF) 患者治疗药的不足
  • 收缩性心脏衰竭 (HF-REF) 患者治疗药的不足
  • 有肾脏功能障碍的患者治疗药的不足
  • 有心脏衰竭发病风险的患者的预防药
  • 心脏衰竭治疗药的服药遵守和最适量服药
    • 未满足需求

第9章 开发平台评估

  • 概要
  • 临床实验中有前途的医药品
  • 开发平台医药品的障碍

第10章 现在、未来市场参与企业

  • 概要
  • 企业策略的趋势
  • Amgen and Cytokinetics
    • 概要
  • Bayer (and Merck & Co.)
  • Bristol-Myers Squibb
  • Les Laboratoires Servier
  • Novartis
  • Zensun
  • AstraZeneca
  • Boehringer Ingelheim (and Eli Lilly)
  • Lexicon

第11章 市场未来展望

  • 全球市场
    • 市场预测
    • 急性心脏衰竭 (AHF)
    • 推动及阻碍市场要素:全世界的课题
  • 美国
    • 市场预测
    • 近几年的主要动向
    • 推动及阻碍市场要素
  • (5EU)欧洲主要5个国家
  • 日本
  • 中国

第12章 附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC189PIDR

Heart failure( HF) is a clinical syndrome where the heart is unable to meet the demands of the body with a sufficient blood supply. This can be due to structural or functional cardiac abnormalities which can be caused by unexpected injury such as myocardial infarction, or an underlying pathogenesis such as hypertension (Krum and Abraham, 2009). The heart then begins to employ compensatory mechanisms that soon become maladaptive - Frank-Starling mechanism, neurohormonal activation and ventricular remodeling. All of which help to relieve stress initially but long term, cause strain on the cardiac muscle and inevitably progression of HF. Heart failure can be either acute or chronic, depending on the manifestation time frame. Heart failure is grouped into subtypes which are defined by measure of ejection fraction - the heart's ability to eject blood.

HF is a global healthcare concern and affected patients suffer from poor quality of life and poor prognosis. Risk factors for HF include; diabetes, hypertension and obesity, all of which are on the rise in the current population. There is a large unmet need in HF for a treatment option that meets clinical end points in reduced mortality and hospitalization.

Key Highlights

  • The main driver of the HF market expansion will be the approval and launch of the SGLT inhibitors for both HF-REF and HF-PEF.
  • Another prominent contributor to sales growth will be the approval of the large number of pipeline therapies across the 8MM.
  • The major global barrier for the HF market will be the annual cost of therapy for new pipeline drugs compared to the standard of care generics, alongside the unwillingness for prescribers to add new drugs to large therapy regimens.
  • The key market opportunities lie in addressing unmet needs through the development of more efficacious drugs for HF patients for acute HF , HF-PEF and HF-mrEF.

Key Questions Answered

  • SGLT inhibitors will enter the market and see a significant uptake in patient shares for the treatment of HF. However, there are high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfill the unmet needs of the HF market?
  • The current late-stage HF pipeline consists of chronic therapies such as Farxiga and Jardiance, post-acute therapies such as omecamtiv mecarbil and Zynquista, and acute therapies such as istaroxime. Will the late-stage drugs make a significant impact on the HF market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • We have seen a significant increase in the HF population, in terms of diagnosed prevalence and there is an increase in the amount of patients treated for HF-REF, HF-PEF and HF-mrEF. How will epidemiological changes impact the growth of the future market?

Scope

  • Overview of HF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HFtherapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global HF market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global HF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HF therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global HF therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Heart Failure: Executive Summary

  • 2.1 The HF Market Will Exhibit Strong Growth Between 2018 and 2028
  • 2.2 Label Expansions of Anti-Diabetic Drugs Will Fuel Market Growth
  • 2.3 The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline
  • 2.4 Farxiga Will Dominate the Branded HF Market
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
    • 4.1.3 Biomarkers/Targets of Interest
  • 4.2 Classification or Staging Systems
  • 4.3 Prognosis

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF
    • 5.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF by EF
    • 5.4.4 Forecast Assumptions and Methods: Acute Hospitalizations
    • 5.4.5 Forecast Assumptions and Methods: Acute Hospitalizations by Worsening CHF, Advanced HF, and De Novo HF
    • 5.4.6 Forecast Assumptions and Methods: Hospital Length of Stay
    • 5.4.7 Forecast Assumptions and Methods: Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
    • 5.4.8 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF
    • 5.4.9 Diagnosed Prevalent Cases of CHF by EF
    • 5.4.10 Diagnosed Prevalent Cases of CHF by NYHA Classes
    • 5.4.11 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF by ACCF/AHA Stages
  • 5.5 Epidemiological Forecast for Heart Failure (2018-2028)
    • 5.5.1 Diagnosed Incident Cases of HF
    • 5.5.2 Age-Specific Diagnosed Incident Cases of HF
    • 5.5.3 Sex-Specific Diagnosed Incident Cases of HF
    • 5.5.4 Diagnosed Incident Cases of HF by EF
    • 5.5.5 AHF Hospitalizations
    • 5.5.6 Hospital Length of Stay for AHF Hospitalization
    • 5.5.7 Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
    • 5.5.8 Diagnosed Prevalent Cases of CHF
    • 5.5.9 Diagnosed Prevalent Cases of CHF by EF
    • 5.5.10 Age-Specific Diagnosed Prevalent Cases of CHF
    • 5.5.11 Sex-Specific Diagnosed Prevalent Cases of CHF
    • 5.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class
    • 5.5.13 Diagnosed Prevalent Cases of CHF with PEF by NYHA Class
    • 5.5.14 Diagnosed Prevalent Cases of CHF with REF by NYHA Class
    • 5.5.15 Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

  • 6.1 Diagnosis Overview
  • 6.2 Treatment Overview
    • 6.2.1 Treatment Guidelines and Leading Prescribed Drugs
    • 6.2.2 Clinical Practice
  • 6.3 US
  • 6.4 5EU
  • 6.5 Japan
  • 6.6 China

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: Heart Failure: Key Metrics in the 8MM
  • Table 2: Types of Chronic HF
  • Table 3: Causes of HF
  • Table 4: Compensatory Mechanisms in HF Patients
  • Table 5: Symptoms of Heart Failure
  • Table 6: Key Diagnostic and Prognostic Biomarkers in HF
  • Table 7: A Comparison of Two HF Classification Systems
  • Table 8: Common Factors that Precipitate AHF
  • Table 9: HF Treatment Guidelines Most Commonly Adhered to by Physicians in the 8MM
  • Table 10: Chronic HF-REF Medications Most Commonly Used in the 8MM
  • Table 11: Country Profile - US
  • Table 12: Country Profile - 5EU
  • Table 13: Country Profile - Japan
  • Table 14: Country Profile - China
  • Table 15: Leading Treatments for HF
  • Table 16: Amgen's HF Portfolio Assessment, 2019
  • Table 17: Bayer's HF Portfolio Assessment, 2019
  • Table 18: Bristol-Myers Squibb HF Portfolio Assessment, 2019
  • Table 19: Servier's HF Portfolio Assessment, 2019
  • Table 20: Novartis' Disease Portfolio Assessment, 2019
  • Table 21: Zensun's Disease Portfolio Assessment, 2019
  • Table 22: AstraZeneca's Disease Portfolio Assessment, 2019
  • Table 23: Lexicon's Disease Portfolio Assessment, 2019
  • Table 24: Heart Failure Market - Global Drivers and Barriers, 2018-2028
  • Table 25: Key Events Impacting Sales for HF in the US, 2018-2028
  • Table 26: HF Market - Global Drivers and Barriers in the US, 2018-2028
  • Table 27: Key Events Impacting Sales for Heart Failure in the 5EU, 2018-2028
  • Table 28: Heart Failure Market - Global Drivers and Barriers in the 5EU, 2018-2028
  • Table 29: Key Events Impacting Sales for Heart Failure in Japan, 2018-2028
  • Table 30: Heart Failure Market - Global Drivers and Barriers in Japan, 2018-2028
  • Table 31: Key Events Impacting Sales for Heart Failure in China, 2018-2028
  • Table 32: Heart Failure Market - Global Drivers and Barriers in China, 2018-2028
  • Table 33: Key Historical and Projected Launch Dates for HF
  • Table 34: Key Historical and Projected Patent Expiry Dates for Heart Failure
  • Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Heart Failure by Country, 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in Heart Failure During the Forecast Period
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2018-2028
  • Figure 4: Changes in Cardiac Structure in HF
  • Figure 5: 8MM, Sources Used to Forecast Hospital Length of Stay for AHF Hospitalization
  • Figure 6: 8MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF
  • Figure 7: 8MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class
  • Figure 8: 8MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N, 2018
  • Figure 9: 8MM, Sex-Specific Diagnosed Incident Cases of HF, All Ages, N, 2018
  • Figure 10: 8MM, Diagnosed Incident Cases of HF by EF, Both Sexes, All Ages, N, 2018
  • Figure 11: 8MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, All Ages, N, 2018
  • Figure 12: 8MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, All Ages, N, 2018
  • Figure 13: 8MM, Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification, Both Sexes, All Ages, N, 2018
  • Figure 14: Diagnostic Algorithm for Chronic HF
  • Figure 15: Diagnostic Algorithm for Acute HF
  • Figure 16: HF based on the ACCF/AHA staging system
  • Figure 17: Classification of Acute HF Patients
  • Figure 18: Management of Acute HF Patients
  • Figure 19: Unmet Needs and Opportunities in Heart Failure
  • Figure 20: Overview of the Development Pipeline in Heart Failure
  • Figure 21: Competitive Assessment of Late-Stage Pipeline Agents in Chronic and Post-Acute Heart Failure, 2018-2028
  • Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in Acute Heart Failure, 2018-2028
  • Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for HF in the 8MM During the Forecast Period
  • Figure 24: Company Portfolio Gap Analysis in Chronic HF, 2018-2028
  • Figure 25: Company Portfolio Gap Analysis in Acute Heart Failure, 2018-2028
  • Figure 26: Global Sales for Chronic HF by Country, 2018 and 2028
  • Figure 27: Global Sales for Acute HF by Country, 2018 and 2028
  • Figure 28: Sales for Chronic HF by Drug Class in the US, 2018 and 2028
  • Figure 29: Sales for Chronic HF by Drug Class in the 5EU, 2018 and 2028
  • Figure 30: Sales for Chronic HF by Drug Class in Japan, 2018 and 2028
  • Figure 31: Sales for Chronic HF by Drug Class in China, 2018 and 2028